How can we assess and measure prognosis for MALT lymphoma? A review of current findings and strategies

Pulmonary mucosa-associated lymphoid tissue lymphoma with Sjögren’s syndrome and literature review: A case report

“…Compared to patients diagnosed with autoimmune diseases or without such a diagnosis, they will not have a poor prognosis in terms of the time to progression. [ 4 ] No treatment for SS is related to the beneficial or harmful effects of lymphoma. [ 6 ] Fully considering these prospective prognostic factors can help clinicians treat patients with SS-related MALT using more appropriate methods.…”

“…Apart from gastric MALT lymphoma, staging is performed using the Ann Arbor Staging system. [ 3 , 4 ] The relative rarity and heterogeneity of patients with pulmonary MALT lymphoma, as well as their different biology, clinical presentation, and behavior, make it difficult to determine the best treatment for these patients. Currently available treatments include surgical resection, chemotherapy, immunotherapy, radiation therapy, and observation.…”

Mucosa-associated lymphoid tissue of nasopharynx: A case report and literature review

“…MALT lymphoma, a disease with distinct pathogenesis triggered by chronic inflammatory processes [6] , is a unique type of low-grade B-cell lymphoma, generally with no specific clinical symptoms, arising from lymphoid populations that are induced by chronic inflammation in extranodal sites [7] . According to Huseh and Chien's literature, MALT lymphoma accounts for 8.6% of the total incidence of nasopharyngeal lymphoma [3] .…”